[ADRO] Aduro Biotech, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11 Change: 0.95 (9.45%)
Ext. hours: Change: 0 (0%)

chart ADRO

Refresh chart

Strongest Trends Summary For ADRO

ADRO is in the medium-term down -74% below S&P in 1 year. In the long-term down -89% below S&P in 3 years and down -98% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities22.31 M Cash From Investing Activities-310 K Cash From Operating Activities-8.47 M Gross Profit
Net Profit-16.62 M Operating Profit-7.28 M Total Assets138.76 M Total Current Assets136.96 M
Total Current Liabilities40.72 M Total Debt1.1 M Total Liabilities51.05 M Total Revenue9.57 M
Technical Data
High 52 week6.83 Low 52 week0.96 Last close1 Last change1.21%
RSI39.29 Average true range0.08 Beta1.32 Volume206.2 K
Simple moving average 20 days-5.61% Simple moving average 50 days-16.96% Simple moving average 200 days-60.26%
Performance Data
Performance Week0.3% Performance Month-25.93% Performance Quart-31.97% Performance Half-72.9%
Performance Year-83.55% Performance Year-to-date-62.12% Volatility daily3.1% Volatility weekly6.94%
Volatility monthly14.22% Volatility yearly49.24% Relative Volume205.44% Average Volume439.51 K
New High New Low

News

2020-05-26 08:11:12 | Aduro Biotech's Shares March Higher, Can It Continue?

2020-05-25 12:00:04 | Aduro Biotech ADRO Upgraded to Buy: What Does It Mean for the Stock?

2020-05-25 11:30:03 | Is Aduro Biotech ADRO Outperforming Other Medical Stocks This Year?

2020-05-19 08:15:10 | Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

2020-05-11 08:35:12 | Is Aduro Biotech ADRO Stock a Solid Choice Right Now?

2020-05-10 08:07:17 | New Forecasts: Here's What Analysts Think The Future Holds For Aduro Biotech, Inc. NASDAQ:ADRO

2020-05-06 06:12:34 | Aduro Biotech, Inc. NASDAQ:ADRO Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

2020-05-04 19:35:11 | Aduro Biotech ADRO Reports Q1 Loss, Tops Revenue Estimates

2020-05-04 16:15:10 | Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results

2020-04-28 12:34:04 | Aduro Biotech ADRO May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2020-04-17 11:30:03 | Is Aduro Biotech ADRO Outperforming Other Medical Stocks This Year?

2020-04-12 08:33:58 | Investors Who Bought Aduro BioTech NASDAQ:ADRO Shares Five Years Ago Are Now Down 93%

2020-04-08 11:30:03 | Aduro Biotech ADRO Down 3.1% Since Last Earnings Report: Can It Rebound?

2020-04-03 17:50:09 | Aduro Biotech ADRO Gains As Market Dips: What You Should Know

2020-04-01 11:30:03 | Has Aduro Biotech ADRO Outpaced Other Medical Stocks This Year?

2020-03-23 17:50:09 | Aduro Biotech ADRO Gains As Market Dips: What You Should Know

2020-03-16 11:30:03 | Is Aduro Biotech ADRO Outperforming Other Medical Stocks This Year?

2020-03-11 14:20:06 | Aduro's ADRO Earnings & Revenues Miss Estimates in Q4

2020-03-09 17:55:09 | Aduro Biotech ADRO Reports Q4 Loss, Lags Revenue Estimates

2020-03-09 16:15:10 | Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

2020-03-05 17:50:10 | Aduro Biotech ADRO Stock Moves -0.6%: What You Should Know

2020-02-28 11:30:04 | Is Aduro Biotech ADRO Stock Outpacing Its Medical Peers This Year?

2020-02-24 16:15:10 | Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference

2020-02-19 12:31:05 | Aduro Biotech ADRO Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2020-02-19 12:00:05 | Aduro Biotech ADRO Upgraded to Strong Buy: Here's Why

2020-02-19 08:15:10 | Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2020-02-06 16:15:10 | Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer

2020-01-10 18:03:18 | East Bay cancer drug developer, jilted by Novartis, to cut 51 jobs

2020-01-10 18:00:38 | Biotechs punch up talking points leading into big Union Square conference

2020-01-09 16:15:10 | Aduro Biotech Announces Corporate Restructuring

2019-12-14 17:18:16 | Hedge Funds Are Betting On Aduro BioTech Inc ADRO

2019-12-09 05:06:57 | Does Aduro BioTech, Inc. NASDAQ:ADRO Have A Volatile Share Price?

2019-12-07 11:31:04 | Aduro Biotech ADRO Up 7.5% Since Last Earnings Report: Can It Continue?

2019-11-08 16:05:00 | Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeti

2019-11-08 12:20:05 | Aduro ADRO Q3 Loss Wider Than Expected, Revenues Rise Y/Y

2019-11-07 19:35:12 | Aduro Biotech ADRO Reports Q3 Loss, Tops Revenue Estimates

2019-11-07 16:05:00 | Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

2019-10-25 07:49:40 | Should You Worry About Aduro BioTech, Inc.'s NASDAQ:ADRO CEO Pay?

2019-10-02 16:05:00 | Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting SITC 2019

2019-09-30 16:05:00 | Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

2019-09-19 09:49:55 | Do Insiders Own Lots Of Shares In Aduro BioTech, Inc. NASDAQ:ADRO?

2019-09-04 08:30:00 | Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 MIW815 in Combination with KEYTRUDA® pembrolizumab for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma HNSCC

2019-09-03 16:05:00 | Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

2019-08-31 09:31:01 | Why Is Aduro Biotech ADRO Down 12.1% Since Last Earnings Report?

2019-08-14 14:32:40 | Who Has Been Selling Aduro BioTech, Inc. NASDAQ:ADRO Shares?

2019-08-05 10:46:02 | Aduro ADRO Earnings Miss in Q2, Revenues Meet Estimates

2019-08-01 16:05:00 | Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results

2019-07-31 10:36:02 | Aduro Biotech ADRO May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-07-16 11:04:03 | AbbVie ABBV Acquires Mavupharma to Boost Cancer Portfolio

2019-06-04 10:32:02 | Aduro Stock Crashes After ASCO Updates on Cancer Candidate